High bleeding risk (HBR) population represents a large proportion of coronary artery disease (CAD) patients undergoing coronary stent implantation.
Managing these patients in terms of decision on the most appropriate course of dual antiplatelet therapy (DAPT) after stent implantation remains a clinical challenge, especially after implantation of newer generation drug eluting stents (DES).
The MASTER DAPT trial aims to compare, an abbreviated versus a prolonged DAPT duration after bioresorbable polymer coated Ultimaster sirolimus-eluting stent implantation in patients presenting HBR features. MASTER DAPT is the first global DAPT study and involves 130 hospitals across 34 countries in Europe (including Switzerland), Asia, Australia, Africa and South America. Up to now, 1850 HBR patients have been successfully enrolled in the study in 96 sites around the world. In total, 4300 HBR are patients needed for study completion
For more information on the MASTER DAPT trial, watch the video in the link below: